Skip to main content

Connective Tissue Diseases

4
Pipeline Programs
5
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
1
1
SirolimusPhase 41 trial
TelitaciceptPhase 2
Active Trials
NCT03688191Unknown20Est. Sep 2019
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
BelimumabPhase 3Monoclonal Antibody
Autonomous Therapeutics
1 program
1
TelitaciceptPhase 21 trial
Active Trials
NCT05998759Recruiting296Est. Dec 2025
Biocorp
BiocorpFrance - Issoire
1 program
CAR-TN/ACell Therapy1 trial
Active Trials
NCT07152223Recruiting20Est. Aug 2029
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Pulmonary function testN/A1 trial
Active Trials
NCT04095351Recruiting120Est. Oct 2034

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsSirolimus
Autonomous TherapeuticsTelitacicept
BiocorpCAR-T
Boehringer IngelheimPulmonary function test

Clinical Trials (4)

Total enrollment: 456 patients across 4 trials

NCT03688191UNION therapeuticsSirolimus

Study of Sirolimus in CTD-TP in China

Start: Sep 2017Est. completion: Sep 201920 patients
Phase 4Unknown
NCT05998759Autonomous TherapeuticsTelitacicept

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Start: Dec 2023Est. completion: Dec 2025296 patients
Phase 2Recruiting
NCT07152223BiocorpCAR-T

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Start: Aug 2025Est. completion: Aug 202920 patients
N/ARecruiting
NCT04095351Boehringer IngelheimPulmonary function test

Connective Tissue Diseases and Lung Manifestations

Start: Dec 2019Est. completion: Oct 2034120 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 456 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.